Evidence map›Paper›PMID 38247410›Full record

ArticleClinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology2024

Exploring Clinical Subgroups of Participants with Major Depressive Disorder that may Benefit from Adjunctive Minocycline Treatment.

Gerard Anmella, Alcy Meehan, Melanie Ashton, Mohammadreza Mohebbi, Giovanna Fico, Chee H Ng, Michael Maes, Lesley Berk, Michele De Prisco, Ajeet B Singh and 9 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Molecular Characteristics of Spontaneous Remission in Major Depressive Disorder: Changes in Serum Acetylcarnitine and Glycerophosphcholine Levels.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 3 countries.

Gerard AnmellaDepartment of Psychiatry and Psychology, Institute of Neuroscience, Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain.ORCID https://orcid.org/0000-0002-6798-4054
Alcy MeehanDeakin University, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, VIC, Australia.ORCID https://orcid.org/0000-0002-5124-0667
Melanie AshtonDeakin University, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, VIC, Australia.ORCID https://orcid.org/0000-0001-6832-4157
Mohammadreza MohebbiDeakin University, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, VIC, Australia.ORCID https://orcid.org/0000-0001-9713-7211
Giovanna FicoDepartment of Psychiatry and Psychology, Institute of Neuroscience, Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain.ORCID https://orcid.org/0000-0003-1785-7126
Chee H NgThe Melbourne Clinic, Department of Psychiatry, University of Melbourne, Melbourne, VIC, Australia.ORCID https://orcid.org/0000-0002-3811-2732
Michael MaesDeakin University, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, VIC, Australia.ORCID https://orcid.org/0000-0002-2012-871X
Lesley BerkDeakin University, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, VIC, Australia.ORCID https://orcid.org/0000-0002-3677-7503
Michele De PriscoDepartment of Psychiatry and Psychology, Institute of Neuroscience, Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain.ORCID https://orcid.org/0000-0002-2032-1181
Ajeet B SinghDeakin University, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, VIC, Australia.ORCID https://orcid.org/0000-0002-0853-7959
Gin S MalhiDepartment of Psychiatry, Northern Clinical School, The University of Sydney, Faculty of Medicine and Health, Sydney, NSW, Australia.ORCID https://orcid.org/0000-0002-4524-9091
Michael BerkDeakin University, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, VIC, Australia.ORCID https://orcid.org/0000-0002-5554-6946
Seetal DoddDeakin University, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, VIC, Australia.ORCID https://orcid.org/0000-0002-7918-4636
Diego Hidalgo-MazzeiDepartment of Psychiatry and Psychology, Institute of Neuroscience, Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain.ORCID https://orcid.org/0000-0002-2693-6849
Iria GrandeDepartment of Psychiatry and Psychology, Institute of Neuroscience, Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain.ORCID https://orcid.org/0000-0002-0137-0666
Isabella PacchiarottiDepartment of Psychiatry and Psychology, Institute of Neuroscience, Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain.ORCID https://orcid.org/0000-0002-7822-0367
Andrea MurruDepartment of Psychiatry and Psychology, Institute of Neuroscience, Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain.ORCID https://orcid.org/0000-0001-6320-4420
Eduard VietaDepartment of Psychiatry and Psychology, Institute of Neuroscience, Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain.ORCID https://orcid.org/0000-0002-0548-0053
Olivia M DeanDeakin University, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, VIC, Australia.ORCID https://orcid.org/0000-0002-2776-3935
Barwon Health · AUInstituto de Salud Carlos III · ESThe University of Melbourne · AUThe University of Sydney · AU

Funding

Wellcome Trust
6 · The paper itself

Abstract

Objective: : To explore illness-related factors in patients with major depressive disorder (MDD) recipients of adjunctive minocycline (200 mg/day) treatment. The analysis included participants experiencing MDD from a 12-week, double blind, placebo-controlled, randomized clinical trial (RCT). Methods: : This is a sub-analysis of a RCT of all 71 participants who took part in the trial. The impact of illness chronicity (illness duration and number of depressive episodes), systemic illness (endocrine, cardiovascular and obesity), adverse effects and minocycline were evaluated as change from baseline to endpoint (12-week) using ANCOVA. Results: : There was a consistent but statistically non-significant trend on all outcomes in favour of the use of adjunctive minocycline for participants without systemic illness, less illness chronicity, and fewer adverse effects. Conclusion: : Understanding the relationship between MDD and illness chronicity, comorbid systemic illness, and adverse effects, can potentially better characterise those individuals who are more likely to respond to adjunctive anti-inflammatory medications.

Indexed as

Clinical trialDepressionInflammationMinocyclineTheragnosticTreatment

Identifiers

PMID38247410
PMCPMC10811397
OpenAlexW4386222993

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.